Glaxosmithkline Pharmaceuticals Ltd (GLAXO)
₹2,494.30
Mkt cap
₹42,607 Cr
P/E ratio
40.50
P/B
18.61
Div yield
2.27%
ROE
45.60%
ROCE
61.40%
EPS (TTM)
₹61.59
Book value
₹134
52W range
2,088–3,121
Sector
Healthcare
Price history
Previous close
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
NSE GLAXOBSE 500660
Health check
Mixed
ValuationFair
ProfitabilityStrong
GrowthLow
TechnicalsNeutral
52-week range
−20.07% from high₹2,494
₹2,088+19.45% from low₹3,121
Current
₹2,494.30
Prev close
₹2,515.10
Day
−0.83%
Price performance
1D
−0.25%
1W
+4.32%
1M
−9.88%
3M
−3.91%
6M
+6.00%
1Y
−9.13%
YTD
+0.42%
Financials
Revenue, profit & margin
P/E ratio
40.5×
GLAXO is 17% above the sector median of 34.5×
GLAXO40.5×
Sector median34.5×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 | |
| Expenses | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 | |
| Operating Profit | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 | |
| OPM % | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% | |
| Other Income | 54 | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 | |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | |
| Depreciation | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 | |
| Profit before tax | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 | |
| Tax % | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% | |
| Net Profit | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 | |
| EPS in Rs | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 | 14.00 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.18% · closed higher next day 21 of last 44
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 12 Feb '24◦ | 17 May '24◦ | 2 Aug '24◦ | 30 Oct '24 | 14 Feb '25◦ | 13 May '25◦ | 1 Aug '25 | 6 Nov '25◦ | 9 Feb '26 | 13 May '26 | 3 Aug '26◦ |
| Earnings day | +1.55% | −6.86% | +3.17% | −2.00% | +1.70% | +15.97% | +3.23% | −7.15% | −0.68% | +1.30% | −1.52% | −0.57% |
| +1 day | +1.50% | −7.98% | +2.51% | −1.09% | +3.14% | +25.71% | +3.23% | −9.28% | −2.52% | +5.59% | −1.31% | −3.48% |
| +5 days | +13.70% | −2.18% | +3.24% | +2.48% | −0.69% | +30.73% | +7.01% | −16.18% | −4.84% | +4.56% | −4.17% | −2.27% |
| +15 days | +16.72% | −8.96% | +13.74% | +1.91% | −10.95% | +31.64% | +22.64% | −11.40% | −1.38% | +1.96% | −11.52% | +11.31% |
| +30 days | +24.86% | −16.82% | +14.51% | −0.76% | −13.35% | +41.56% | +16.86% | −13.42% | −2.94% | −7.04% | −3.84% | +7.28% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 57 Per Share | 57.00 | 29 May '26 | 29 May '26 |
Shareholding
as of Sep 202675.00%Promoter
Promoters75.00%
FIIs4.75%0.04
DIIs8.47%0.66
Public11.77%0.65
Government0.00%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,761.00 | 33.45 | 4,22,523 | 0.91% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,664.00 | 86.11 | 2,56,549 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,580.00 | 80.24 | 1,74,208 | 0.83% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,244.00 | 90.49 | 1,21,246 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,184.40 | 24.27 | 1,18,144 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,345.00 | 40.10 | 1,12,265 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,358.00 | 35.33 | 1,09,709 | 0.96% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Glaxosmi. Pharma | ₹2,515.10 | 40.47 | 42,607 | 2.27% | 237 | +15.69% | 938 | +16.55% | 61.41% |
| Median: 159 Co. | ₹439.10 | 34.49 | 1,934 | 0.08% | 14 | +22.88% | 170 | +18.91% | 15.11% |
Filings
Annual reports15
Concall transcripts25
TranscriptAug 2026PPTAug 2026TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024TranscriptAug 2024TranscriptMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptMar 2023TranscriptAug 2022PPTAug 2022PPTAug 2021
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - GSK Pharma schedules digital investor/analyst group meeting on 4 November 2026.Board Meeting Intimation for To Consider, Approve And Take On Record The Un-Audited Financial Results For The Second Quarter & Half Year Ended 30Th September 2026. 13 Oct - Board to meet on 3 November 2026 to consider Q2 and half-year unaudited results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Oct - Submitted Regulation 74(5) certificate for quarter ended 30 September 2026.Closure of Trading Window 25 SepShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 15 Sep